Ortin Global
Healthcare
ORTINGLOBE NSE
₹13.80 +0.76 (+5.83%)
- P/E
- Not meaningful: loss-making over the last twelve months
Close 4 Nov 2026 ₹13.80 +2.18 +18.8% 1Y
Start ₹11.62
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- −33.90%
- Debt to Equity
- 0.81
- EPS (TTM)
- −₹1.10
- Book Value
- ₹1.52
- Market Cap
- —
- P/E (TTM)
- Not meaningful: loss-making over the last twelve months
- P/B
- 9.08
- ROE
- −48.40%
- Dividend Yield
- 0.00%
- EBITDA
- −₹70.00 L
- 52W High
- ₹21.30
- 52W Low
- ₹11.00
- Day Range
- ₹13.12 – ₹13.97
- Volume
- 4,227
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Ortin Global (this company) | ₹13.80 | — | ₹11 Cr | 9.08 | 0.00% | −48.40% | −33.90% | ₹0 Cr | −₹1 Cr |
| Median 8 companies | ₹1,587.70 | 38.81 | ₹1,25,337 Cr | 6.93 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
30 Poor
Data confidence 91/100
surveillance:GSM
Category scores
- Quality
- 23
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 29
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 80
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 14
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 39
- Weak
- Trend strength, vol-adjusted 12% weight
- Ownership
- 35
- Poor
- FII/DII/promoter flows 24% weight
Capped: a governance trigger overrides the
fundamentals here (surveillance:GSM ≤ 40).
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
10- Stock is trading at 9.46 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -58.5% over past five years.
- Promoter holding is low: 1.24%
- Company has a low return on equity of -73.1% over last 3 years.
- Contingent liabilities of Rs.24.3 Cr.
- Company might be capitalizing the interest cost
- Company has high debtors of 730 days.
- Promoter holding has decreased over last 3 years: -6.13%
- Working capital days have increased from 1,625 days to 2,993 days
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 8 | 5 | 6 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bearish | 6 | 0 | 4 |
Oscillators
Neutral
Bearish
2
Neutral
5
Bullish
2
Overall
Bearish
Bearish
8
Neutral
5
Bullish
6
Moving Averages
Strong Bearish
Bearish
6
Neutral
0
Bullish
4
Key readings
- RSI (14)
- 48.86
- Neutral
- MACD (12,26,9)
- −0.44
- Bullish
- SMA (50)
- 14.74
- Bearish
- SMA (200)
- 15.28
- Bearish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | −47.49% |
|---|---|
| 5Y | −58.54% |
| 3Y | −74.46% |
| 1Y | −70.59% |
| TTM | +32.00% |
Net profit
| 10Y | Turned to loss |
|---|---|
| 5Y | Turned to loss |
| 3Y | Loss widened by ₹0.65 Cr |
| 1Y | Loss narrowed by ₹0.11 Cr |
| TTM | Loss narrowed by ₹0.02 Cr |
Operating cash flow
| 10Y | Turned negative |
|---|---|
| 5Y | Turned negative |
| 3Y | Outflow widened by ₹0.31 Cr |
| 1Y | Outflow widened by ₹0.15 Cr |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | Tiny sales |
|---|---|
| 5Y | Tiny sales |
| 3Y | Tiny sales |
| 1Y | Tiny sales |
| TTM | +90.30 pp |
Revenue by year
| Mar 2017 | ₹61.57 Cr |
|---|---|
| Mar 2018 | ₹79.63 Cr |
| Mar 2019 | ₹168 Cr |
| Mar 2020 | ₹197 Cr |
| Mar 2021 | ₹8.16 Cr |
| Mar 2022 | ₹8.23 Cr |
| Mar 2023 | ₹6.00 Cr |
| Mar 2024 | ₹2.01 Cr |
| Mar 2025 | ₹0.34 Cr |
| Mar 2026 | ₹0.10 Cr |
Net profit by year
| Mar 2017 | ₹0.50 Cr |
|---|---|
| Mar 2018 | ₹0.68 Cr |
| Mar 2019 | ₹1.28 Cr |
| Mar 2020 | −₹0.56 Cr |
| Mar 2021 | ₹0.95 Cr |
| Mar 2022 | −₹0.40 Cr |
| Mar 2023 | −₹0.09 Cr |
| Mar 2024 | −₹8.04 Cr |
| Mar 2025 | −₹0.85 Cr |
| Mar 2026 | −₹0.74 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.57 | 0.27 | 0.14 | 0.3 | 0.21 | 0.05 | 0.03 | 0.09 | 0.08 | 0.01 | 0.01 | 0.3 | 0.01 |
| Expenses | 1.39 | 1.17 | 2.74 | 3.35 | 0.31 | 0.5 | 0.16 | 0.25 | 0.24 | 0.51 | 0.06 | 0.31 | 0.34 |
| Operating Profit | 0.18 | −0.9 | −2.6 | −3.05 | −0.1 | −0.45 | −0.13 | −0.16 | −0.16 | −0.5 | −0.05 | −0.01 | −0.33 |
| OPM % | 11.46% | −333.33% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | −47.62% | −900% | −433.33% | −177.78% | −200% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | −500% | −3.33% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0.11 | 0.15 | 0.14 | 0.08 | 0 | 0.02 | −0.01 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.06 | 0.06 | 0.06 | 0.05 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0.02 | −1.11 | −2.8 | −3.18 | −0.1 | −0.47 | −0.1 | −0.16 | −0.16 | −0.5 | −0.05 | −0.01 | −0.33 |
| Tax % | 0% | 1.8% | −0.71% | 30.19% | 0% | 0% | 10% | 0% | 6.25% | 0% | 0% | 0% | 0% |
| Net Profit | 0.02 | −1.12 | −2.79 | −4.14 | −0.1 | −0.47 | −0.11 | −0.16 | −0.18 | −0.5 | −0.05 | −0.01 | −0.34 |
| EPS (₹) | 0.02 | −1.38 | −3.43 | −5.09 | −0.12 | −0.58 | −0.14 | −0.2 | −0.22 | −0.61 | −0.06 | −0.01 | −0.42 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60.29 | 62.72 | 61.57 | 79.63 | 168 | 197 | 8.16 | 8.23 | 6 | 2.01 | 0.34 | 0.1 | 0.33 |
| Expenses | 53.8 | 56.83 | 56.12 | 74.22 | 161 | 192 | 6.92 | 7.85 | 5.47 | 6.4 | 1.23 | 1.13 | 1.22 |
| Operating Profit | 6.49 | 5.89 | 5.45 | 5.41 | 6.68 | 5.7 | 1.24 | 0.38 | 0.53 | −4.39 | −0.89 | −1.03 | −0.89 |
| OPM % | 10.76% | 9.39% | 8.85% | 6.79% | 3.99% | 2.89% | 15.2% | 4.62% | 8.83% | −218.41% | −261.76% | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | −269.7% |
| Other Income | 0 | 0.57 | 0.32 | 0.45 | 0.13 | 0.18 | 0.05 | 0.19 | 0.01 | −1.98 | 0.06 | 0.31 | 0 |
| Interest | 3.52 | 3.42 | 2.94 | 3.49 | 3.22 | 3.21 | 0.87 | 0.81 | 0.4 | 0.48 | 0 | 0 | 0 |
| Depreciation | 1.64 | 1.65 | 1.7 | 1.69 | 1.75 | 1.96 | 0.29 | 0.29 | 0.25 | 0.23 | 0.01 | 0 | 0 |
| PBT | 1.33 | 1.39 | 1.13 | 0.68 | 1.84 | 0.71 | 0.13 | −0.53 | −0.11 | −7.08 | −0.84 | −0.72 | −0.89 |
| Tax % | 32.33% | 41.01% | 55.75% | 0% | 30.43% | 181.69% | −623.08% | −24.53% | −18.18% | 13.56% | 1.19% | 2.78% | — |
| Net Profit | 0.9 | 0.83 | 0.5 | 0.68 | 1.28 | −0.56 | 0.95 | −0.4 | −0.09 | −8.04 | −0.85 | −0.74 | −0.9 |
| EPS (₹) | 0.53 | 0.49 | 0.3 | 0.4 | 0.76 | −0.33 | 1.17 | −0.49 | −0.11 | −9.89 | −1.05 | −0.91 | −1.1 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 8.13 | 8.13 | 8.13 | 8.13 | 8.13 | 8.13 |
| Reserves | 5.5 | 6.33 | 6.46 | 7.14 | 8.15 | 6.88 | 3.22 | 2.83 | 2.73 | −5.31 | −6.15 | −6.89 |
| Borrowings | 20.96 | 20.85 | 17.34 | 17.34 | 19.47 | 19.57 | 6.94 | 6.14 | 6.45 | 1.8 | 0.25 | 1.01 |
| Other Liabilities | 23.87 | 21.22 | 20.79 | 32.24 | 60.53 | 73.13 | 2.97 | 3.61 | 3.89 | 2.05 | 1.55 | 2.4 |
| Total Liabilities | 67.27 | 65.34 | 61.53 | 73.66 | 105 | 117 | 21.26 | 20.71 | 21.2 | 6.67 | 3.78 | 4.65 |
| Fixed Assets | 21.83 | 21.63 | 20.69 | 20.03 | 21.29 | 22.45 | 14.38 | 14.21 | 13.96 | 0.01 | 0 | 0.01 |
| CWIP | 0 | 0 | 0.35 | 0.4 | 0.53 | 0.43 | 0.43 | 0.43 | 0.43 | 0 | 0 | 0 |
| Investments | 0.03 | 0.03 | 0.07 | 0.08 | 0.08 | 0.07 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 45.41 | 43.68 | 40.42 | 53.15 | 83.19 | 93.57 | 6.45 | 6.07 | 6.81 | 6.66 | 3.78 | 4.64 |
| Total Assets | 67.27 | 65.34 | 61.53 | 73.66 | 105 | 117 | 21.26 | 20.71 | 21.2 | 6.67 | 3.78 | 4.65 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | −1.38 | 0.52 | 1.94 | 1.56 | 6.52 | 3.3 | 18.03 | 2.15 | −0.25 | −4.79 | −0.41 | −0.56 |
| Investing | 0.22 | −0.86 | −1.26 | −0.9 | −3.27 | −3.09 | 0.07 | −0.13 | 0.01 | 12 | 0 | 0.04 |
| Financing | 1.73 | 0.27 | −0.82 | 0.07 | −2.89 | −1.33 | −9.86 | −0.48 | 0.9 | −3.49 | 0.33 | 0.75 |
| Net Cash Flow | 0.58 | −0.07 | −0.14 | 0.73 | 0.37 | −1.12 | 8.25 | 1.55 | 0.66 | 3.72 | −0.09 | 0.23 |
| Free Cash Flow | −1.38 | −0.92 | 0.83 | 0.77 | 3.38 | 0.28 | 18.03 | 2.02 | −0.24 | 7.21 | −0.41 | −0.52 |
| CFO/EBITDA | −14 | 17 | 47 | 40 | 104 | 72 | 1,454 | 566 | −47 | 80 | 46 | 54 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 53.13 | 90.35 | 100 | 82.43 | 68.71 | 175 | 144 | 208 | 321 | 279 | 730 |
| Inventory Days | 192 | 149 | 158 | 152 | 100 | 118 | 169 | 136 | 280 | 4.92 | 34.76 | 0 |
| Days Payable | 151 | 24.82 | 108 | 143 | 145 | 156 | 124 | 61.88 | 167 | 7.87 | 69.52 | — |
| Cash Conversion Cycle | 145 | 177 | 140 | 109 | 37.38 | 30.7 | 220 | 218 | 321 | 318 | 244 | 730 |
| Working Capital Days | 29 | 16.24 | 37.29 | 41.48 | 16.82 | 11.24 | −87.22 | −109 | −43.19 | 358 | 1,524 | 2,993 |
| ROCE % | 12.07% | 10.92% | 9.57% | 9.44% | 11.77% | 8.94% | 3.24% | 1.58% | 1.8% | −40.58% | −25.11% | −33.93% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Ortin Global insights
63 extracted metrics across FY10–FY27.
Documents
- General announcements 10 Oct 2026
Frequently Asked Questions about Ortin Global
What does Ortin Global Ltd do?
Incorporated in 1986, Ortin Laboratories Ltd manufactures pharmaceutical formulations.
Where is Ortin Global Ltd (ORTINGLOBE) listed?
Ortin Global Ltd trades as ORTINGLOBE on the NSE and under code 539287 on the BSE.
Which sector does Ortin Global Ltd belong to?
Ortin Global Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Ortin Global Ltd?
Over the last 52 weeks Ortin Global Ltd has traded between ₹11 and ₹21.3 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Ortin Global Ltd?
Ortin Global Ltd reported a return on equity of -48.40%. Its debt-to-equity ratio is 0.81.
Company Information
Incorporated in 1986, Ortin Laboratories Ltd manufactures pharmaceutical formulations.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ORTINGLOBE.md for Ortin Global Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.